Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis oil in advanced untreatable hepatocellular carcinoma
NCT06518434Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Transvamix in hepatocellular carcinoma (HCC), sponsored by University Medical Center Groningen. Primary endpoint: Tumor size at 9 months. Started Apr 2021; status: recruiting.
02
Drugs
Transvamix
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06518434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518434.